Kaihui Cui

Kaihui Cui

Auto-generated profile, based on publicly available information

Kaihui Cui

School of Metallurgical and Ecological Engineering, University of Science and Technology Beijing, Beijing 100083, P. R. China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2023 in Journal of Environmental Chemical Engineering
Verified
Journal Article
Closed access
KCKaihui Cui
Kaihui Cui
JWJinle Wei
Jinle Wei
HZHaitao Zhou
Haitao Zhou
LXLinchen Xie
Linchen Xie
WXWenliang Xiong
Wenliang Xiong
Kun HuangKun Huang
Kun Huang



17 October 2025 in Science Advances
Verified
Journal Article
Open access
JZJinyu Zhu
Jinyu Zhu
KCKaihui Cui
Kaihui Cui
WZWenyuan Zhou
Wenyuan Zhou
XZXin Zhou
Xin Zhou
YYYuan Yao
Yuan Yao
NLNan Li
Nan Li
Osimertinib (Osi) resistance limits its efficacy in EGFR-mutant non–small cell lung cancer (NSCLC). Here, we developed a pH-responsive cationic nanovesicle ( 124 I/Cy5.5-sO@FCLs), equipped with dual-modal positron emission tomography (PET) and fluorescence imaging capabilities, to enable dynamic monitoring of the role of ribonucleotide reductase M2 subunit (RRM2) disruption in overcoming Osi resistance and enhance targeted anticancer efficacy in NSCLC. RRM2 was identified as a critical driver of poor prognosis and Osi resistance in NSCLC. The 124 I/Cy5.5-sO@FCLs enabled real-time tracking of tumor targeting and biodistribution, and CRISPR-Cas9–mediated RRM2 disruption efficiently reversed Osi resistance and potentiated synergistic anticancer effects, which was attributed to counteracting TGF-β/Smad2/3–mediated epithelial-mesenchymal transition (EMT) and amplifying cGAS/STING-induced ferroptosis. Furthermore, the nanovesicles triggered STING-dependent immunogenic cell death (ICD), stimulating tumor infiltration of dendritic cells (DCs) and T cells; combination with anti–PD-L1 therapy augmented NSCLC regression. Collectively, 124 I/Cy5.5-sO@FCLs integrate gene editing with targeted therapies while enabling dynamic, quantitative monitoring, providing an approach for precision-targeted treatment in Osi-resistant NSCLC.


29 July 2024 in Industrial & Engineering Chemistry Research
Verified
Journal Article
Closed access
ZYZhizhuo Yang
Zhizhuo Yang
HZHaitao Zhou
Haitao Zhou
SLShirong Li
Shirong Li
KCKaihui Cui
Kaihui Cui
Kun HuangKun Huang
Kun Huang